Does CASIMERSEN Cause Product dose omission issue? 253 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 253 reports of Product dose omission issue have been filed in association with CASIMERSEN (AMONDYS 45). This represents 33.0% of all adverse event reports for CASIMERSEN.
253
Reports of Product dose omission issue with CASIMERSEN
33.0%
of all CASIMERSEN reports
0
Deaths
2
Hospitalizations
How Dangerous Is Product dose omission issue From CASIMERSEN?
Of the 253 reports, 2 (0.8%) required hospitalization.
Is Product dose omission issue Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for CASIMERSEN. However, 253 reports have been filed with the FAERS database.
What Other Side Effects Does CASIMERSEN Cause?
No adverse event (166)
Poor venous access (101)
Device issue (76)
Intentional dose omission (74)
Malaise (36)
Pyrexia (31)
Covid-19 (29)
Influenza (18)
Pneumonia (17)
Product distribution issue (17)
What Other Drugs Cause Product dose omission issue?
DUPILUMAB (18,189)
USTEKINUMAB (9,405)
GUSELKUMAB (9,267)
LENALIDOMIDE (8,145)
MEPOLIZUMAB (5,873)
TOFACITINIB (5,646)
VOXELOTOR (5,122)
BELIMUMAB (4,671)
SECUKINUMAB (4,572)
APREMILAST (4,460)
Which CASIMERSEN Alternatives Have Lower Product dose omission issue Risk?
CASIMERSEN vs CASIRIVIMAB
CASIMERSEN vs CASIRIVIMAB\IMDEVIMAB
CASIMERSEN vs CASPOFUNGIN
CASIMERSEN vs CATEQUENTINIB
CASIMERSEN vs CC-4047